Atlas Trials

Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

Clinical trial NCT05495828 · UNKNOWN

Trial details

NCT number
NCT05495828
Sponsor
Peking University People's Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
B-cell Lymphoma
Start date
2023-11-10
Primary completion
2024-12-10
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.